{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:36:06Z","timestamp":1790375766470,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.lungcan.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T00:00:48Z","timestamp":1491955248000},"page":"228-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"special_numbering":"C","title":["Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S\/R) together with C797S\/G and L792F\/H mutations in one EGFR (L858R\/T790M) NSCLC patient who progressed on osimertinib"],"prefix":"10.1016","volume":"108","author":[{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola W.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Albacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"December","key":"10.1016\/j.lungcan.2017.04.003_bib0010","article-title":"Osimertinib for the treatment of metastatic epidermal growth factor T970M positive non-small cell lung cancer","author":"Khozin","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"December","key":"10.1016\/j.lungcan.2017.04.003_bib0015","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M- positive lung cancer","author":"Mok","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping","volume":"12","author":"Ou","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0025","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0030","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","article-title":"Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR Inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain","volume":"1","author":"Yu","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2016.05.015","article-title":"High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression","volume":"98","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"issue":"June","key":"10.1016\/j.lungcan.2017.04.003_bib0040","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0045","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0050","series-title":"16th World Conference in Lung Cancer","article-title":"Identification of on-target mechanisms of resistance to EGFR inhibitors using cfDNA next-generation sequencing","author":"Lin","year":"2016"},{"key":"10.1016\/j.lungcan.2017.04.003_bib0055","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0060","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-12-1894","article-title":"DNA-mutation inventory to refine and enhance cancer treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy","volume":"19","author":"Yeh","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802\/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib","volume":"9","author":"Ou","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0070","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0085","article-title":"Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osiemrtinib in advanced NSCLC","author":"Chen","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.003_bib0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1016\/j.lungcan.2019.08.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000}}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:23:13Z","timestamp":1759234993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217302908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":18,"alternative-id":["S0169500217302908"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.lungcan.2019.08.013","asserted-by":"object"}]},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S\/R) together with C797S\/G and L792F\/H mutations in one EGFR (L858R\/T790M) NSCLC patient who progressed on osimertinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}